Skin Cancer

The information below is intended for use by health care providers only. Please consult with your health care provider for more information about clinical trials.

S1801 Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

Study Details

  • Study Site/Tumor Location: Melanoma
  • Study Location: All Premier
  • Ages eligible for study: 18 years and older
  • Genders eligible for study: Both
  • Principal Investigator: Dr. Gross
  • Other Physicians who can consent: Dr. Bane, Dr. Cheruvu, Dr. Ditzel, Dr. Guy, Dr. Jilani, Dr. Kathula, Dr. Koduri, Dr. Marinella, Dr. Miller, Dr. Okoye, Dr. Rajsheker, Dr. Romer, Dr. Sabagh, Dr. Setzkorn, Dr. Sheth, Dr. Steinmetz

Study Contact Information